Gout: Causes, Treatments, and Lifestyle Management

Gout is the most common form of inflammatory arthritis in adults, affecting an estimated 9.2 million people in the United States alone. It is caused by the deposition of monosodium urate crystals in joints and surrounding tissues when serum uric acid levels exceed the saturation point of approximately 6.8 mg/dL. The disease is characterized by acute, intensely painful flares that typically involve a single joint—most often the first metatarsophalangeal joint of the big toe—followed by symptom-free intervals. Without effective long-term management, gout can progress to chronic tophaceous disease with permanent joint damage, kidney stones, and reduced quality of life. This article synthesizes current evidence from the American College of Rheumatology (ACR) 2020 guideline, the European Alliance of Associations for Rheumatology (EULAR) 2016 recommendations, and newer data presented at EULAR 2026 to provide a practical framework for understanding, treating, and living with gout.

What Is Gout and What Causes It?

Gout results from hyperuricemia—an elevated concentration of uric acid in the blood. Uric acid is the end-product of purine metabolism. Purines are nitrogen-containing compounds that come from two sources: endogenous production (the body breaks down its own cells) and dietary intake (purine-rich foods and beverages). Under normal conditions, the kidneys excrete roughly two-thirds of daily uric acid production, and the gastrointestinal tract handles the remainder. Hyperuricemia develops when the body produces too much uric acid, the kidneys fail to excrete enough, or both mechanisms coexist.

When serum urate surpasses the solubility threshold of 6.8 mg/dL, monosodium urate crystals can form and deposit in synovial fluid, cartilage, bones, tendons, and bursae. These crystals trigger an intense inflammatory response mediated by the NLRP3 inflammasome, which activates interleukin-1β (IL-1β) and recruits neutrophils to the joint space. The result is the characteristic inflammatory cascade responsible for the erythema, warmth, swelling, and excruciating pain of an acute gout flare.

The CDC notes that gout flares can last days to weeks, and over time, if left untreated, attacks become more frequent and last longer. Chronic hyperuricemia can also lead to tophi—lumps of urate crystals deposited under the skin—and uric acid kidney stones. The CDC provides detailed patient education on gout at CDC Gout Overview.

Risk Factors and Epidemiology

Gout is more common in men than in women, with a male-to-female ratio of approximately 3:1. In women, the risk increases after menopause as estrogen levels decline, since estrogen promotes urinary uric acid excretion. The prevalence of gout rises with age and is particularly high among men over 40 and postmenopausal women.

Modifiable risk factors include dietary patterns high in purines and fructose, obesity, hypertension, chronic kidney disease, and the use of certain medications such as thiazide and loop diuretics, low-dose aspirin, and cyclosporine. Non-modifiable risk factors include genetics—genome-wide association studies have identified several urate transporter genes, including SLC2A9 and ABCG2, that strongly influence serum urate levels—and family history. The CDC reports that gout risk is also elevated in individuals with heart failure, insulin resistance, diabetes, and poor kidney function.

The global burden of gout has risen substantially over recent decades, driven by aging populations, increasing rates of obesity and metabolic syndrome, and dietary shifts toward purine-dense foods and sugar-sweetened beverages. A 2026 review in the Journal of International Medical Research emphasizes that gout is now a significant public health concern worldwide, and comprehensive management strategies are urgently needed at the population level.

Recognizing an Acute Gout Flare

The hallmark of an acute gout flare is the rapid onset of severe pain, swelling, erythema, and warmth in a joint, often developing over a few hours and frequently awakening the patient from sleep. The first metatarsophalangeal joint (podagra) is involved in approximately 50% of initial attacks. Other commonly affected sites include the midfoot, ankle, knee, wrist, fingers, and elbow. The pain is often described as throbbing, crushing, or excruciating—so intense that even the weight of a bedsheet on the joint is unbearable.

Flares are typically self-limited, resolving within 3–14 days even without treatment. However, untreated or undertreated flares may resolve more slowly and recur with greater frequency over time. The intercritical period (the symptom-free interval between flares) tends to shorten as the disease progresses. Some patients develop chronic gouty arthritis with persistent low-grade joint inflammation and discomfort, even between flares.

Tophi are pathognomonic for chronic gout. These firm, chalky subcutaneous nodules develop at characteristic locations including the helix of the ear, the olecranon bursa, the Achilles tendon, and the extensor surfaces of the forearms and hands. Tophi can erode adjacent bone and cause structural joint damage, functional impairment, and cosmetic deformity. Renal manifestations include uric acid nephrolithiasis (kidney stones) and, in severe cases, urate nephropathy.

Diagnosis and Differential

The gold standard for diagnosing gout is the identification of monosodium urate crystals in synovial fluid or tophus aspirate using polarized light microscopy. Crystals appear negatively birefringent and needle-shaped. Joint aspiration also serves to rule out septic arthritis, which is a medical emergency and can coexist with gout—approximately 1–2% of gout patients have concomitant septic arthritis.

In clinical practice, the diagnosis is often made on the basis of the typical presentation alone, especially in patients with a history of podagra. The ACR and EULAR have published validated classification criteria that combine clinical, laboratory, and imaging features. Key clinical criteria include the number and location of involved joints, the time course of symptom onset (less than 24 hours), and the presence of tophi. Laboratory findings supporting the diagnosis include serum urate greater than 6.8 mg/dL (though levels can be normal during a flare due to the acute-phase inflammatory response), and imaging findings such as cortical bone erosion with overhanging edges on plain radiography, the double-contour sign on ultrasound, or urate deposition on dual-energy CT.

The differential diagnosis includes pseudogout (calcium pyrophosphate deposition disease), septic arthritis, psoriatic arthritis, rheumatoid arthritis, reactive arthritis, cellulitis, and trauma. Serum urate levels alone are insufficient for diagnosis because many people with hyperuricemia never develop gout, and urate levels may be falsely normal during an acute attack. The Mayo Clinic offers a comprehensive overview of gout diagnosis and treatment at Mayo Clinic Gout.

Treating Acute Flares

The goal of acute flare treatment is to terminate pain and inflammation as rapidly as possible. Therapy should be initiated within the first 12 to 24 hours for maximum efficacy. The ACR 2020 guideline strongly recommends first-line use of nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids (oral, intra-articular, or intramuscular), with the choice depending on patient-specific factors such as renal function, comorbidities, and concomitant medications.

NSAIDs such as naproxen (500 mg twice daily), indomethacin (50 mg three times daily), or ibuprofen (800 mg three times daily) are highly effective and widely used. They should be prescribed for 5–7 days or until the flare resolves. A proton pump inhibitor should be considered for gastroprotection in patients at risk for NSAID-related gastropathy. NSAIDs are contraindicated in patients with advanced chronic kidney disease, active peptic ulcer disease, or significant cardiovascular disease.

Colchicine is a plant-derived alkaloid that inhibits microtubule polymerization and dampens the inflammatory response to urate crystals. The low-dose regimen validated by the AGREE trial—1.2 mg at first sign of a flare followed by 0.6 mg one hour later—is as effective as high-dose colchicine with significantly fewer gastrointestinal side effects. After the initial two-dose loading, some patients require prophylaxis-level dosing (0.6 mg once or twice daily) until the flare subsides. Colchicine requires dose adjustment in chronic kidney disease and has important drug interactions with clarithromycin, statins, and cyclosporine.

Glucocorticoids are an excellent option for patients with contraindications to NSAIDs and colchicine. Oral prednisone or prednisolone at 30–35 mg daily for 3–5 days, then tapered over 7–10 days, is effective. Intra-articular corticosteroid injection (e.g., triamcinolone acetonide 40–80 mg for large joints) provides rapid, targeted relief and is particularly useful when a single joint is affected and after septic arthritis has been excluded. Intramuscular triamcinolone (60 mg as a single dose) offers systemic relief for patients unable to take oral medications.

For severe flares involving multiple joints or resistant to monotherapy, the ACR conditionally recommends combination therapy—for example, colchicine plus an NSAID, or colchicine plus a corticosteroid. During an acute flare, bed rest, elevation of the affected limb, and application of ice packs for 15–20 minutes several times daily provide symptomatic benefit. The Harvard Health Publishing guide on gout management provides further practical detail at Harvard Health Gout.

Urate-Lowering Therapy

Urate-lowering therapy (ULT) is the cornerstone of long-term gout management. The ACR 2020 guideline strongly recommends a treat-to-target strategy: start with a low dose of a ULT medication and escalate gradually until the serum urate target of less than 6 mg/dL is achieved and maintained. For patients with tophi, a more aggressive target of less than 5 mg/dL may be pursued to accelerate tophus dissolution.

Allopurinol is the first-line ULT agent for most patients. It is a xanthine oxidase inhibitor that reduces uric acid production. The recommended starting dose is 100 mg daily (50 mg daily in patients with stage 4 or higher chronic kidney disease), titrated upward every 2–4 weeks based on serum urate response. The mean effective dose is approximately 300–400 mg daily, though doses up to 800 mg daily may be required in some patients. Allopurinol is generally well-tolerated; the most serious adverse event is allopurinol hypersensitivity syndrome, which manifests as fever, rash, eosinophilia, and potentially life-threatening Stevens-Johnson syndrome. This risk is increased in patients with the HLA-B*58:01 allele, which is more common in people of Han Chinese, Thai, and Korean descent. Screening for HLA-B*58:01 is conditionally recommended in high-risk populations before starting allopurinol.

Febuxostat is a non-purine selective xanthine oxidase inhibitor used as a second-line agent when allopurinol is not tolerated or is contraindicated. It is dosed at 40 mg or 80 mg daily. The CARES trial raised concerns about an increased risk of cardiovascular mortality with febuxostat compared with allopurinol, leading the FDA to require a black-box warning. Febuxostat should be avoided in patients with a history of myocardial infarction or stroke.

Probenecid is a uricosuric agent that increases renal uric acid excretion by inhibiting the urate transporter URAT1 in the proximal tubule. It is an alternative for patients who do not achieve target urate levels on xanthine oxidase inhibitors or who have contraindications to them. Probenecid requires adequate renal function (creatinine clearance greater than 50 mL/min) and is less effective in patients with overproduction hyperuricemia. It should not be used in patients with a history of uric acid kidney stones unless combined with aggressive hydration and urinary alkalinization.

Pegloticase is a recombinant uricase administered intravenously that rapidly degrades uric acid to allantoin. It is reserved for patients with severe, refractory gout who have failed or cannot tolerate conventional oral ULT. The ACR 2020 guideline strongly recommends pegloticase for patients who have not reached target urate levels and have frequent flares (two or more per year) or tophi despite optimized oral therapy. Pegloticase is highly effective but can cause infusion reactions and anaphylaxis, and its use requires premedication and infusion setting precautions.

When ULT is initiated, flare prophylaxis with low-dose colchicine (0.6 mg once or twice daily) or low-dose NSAIDs is strongly recommended for the first 3–6 months, because starting ULT can paradoxically trigger flares as the urate pool mobilizes and crystals are shed from joint surfaces. A clinical trial demonstrated that prophylactic therapy reduced flares during the initiation period by 64%. Patients must be counseled not to stop their ULT during a flare but rather to treat the flare separately and continue the ULT. The National Institutes of Health (NIH) provides detailed information on gout treatment and clinical trials at NIH Gout Information.

Dietary and Lifestyle Modifications

While medication is the foundation of gout treatment, dietary and lifestyle modifications can lower serum urate by 1–2 mg/dL and reduce the frequency and severity of flares. The ACR conditionally recommends several dietary modifications, though it acknowledges that genetic factors account for a substantial portion of interindividual variation in urate levels, meaning lifestyle changes alone are rarely sufficient for patients with established gout.

Purine-Rich Foods. Patients should limit consumption of red meat (beef, pork, lamb), organ meats (liver, kidney, sweetbreads), and certain seafoods (sardines, anchovies, mussels, scallops, herring). The landmark Health Professionals Follow-Up Study found that men in the highest quintile of meat intake had a 40% increased risk of incident gout, and those in the highest seafood quintile had a 50% increased risk, compared with the lowest quintiles. Importantly, purine-rich vegetables such as peas, beans, lentils, spinach, mushrooms, and cauliflower have not been associated with an increased risk of gout and do not need to be restricted.

Alcohol. Alcohol, particularly beer and spirits, increases uric acid production and decreases urinary excretion. Beer contains high levels of guanosine, a purine nucleoside that is readily absorbed and metabolized to uric acid. Moderate wine consumption does not appear to carry the same risk, but the ACR conditionally recommends limiting all alcohol, especially beer and liquor. The risk is dose-dependent: each additional beer per day increases the relative risk of gout by approximately 50%.

Sugary Beverages and Fructose. Fructose, especially from sugar-sweetened beverages, promotes hyperuricemia through ATP depletion and increased purine turnover. Soft drinks and fruit juices sweetened with high-fructose corn syrup or sucrose should be avoided. The Nurses’ Health Study found that women who consumed one or more servings of sugar-sweetened soda per day had a 74% higher risk of developing gout compared with those who consumed less than one serving per month.

Weight Management. Obesity is strongly associated with hyperuricemia and gout. Weight loss reduces serum urate levels, decreases the risk of incident gout, and lowers flare frequency in patients with established disease. The ACR conditionally recommends weight loss for patients with gout who are overweight or obese. As little as 5–10% weight loss can produce meaningful improvements. However, crash dieting and fasting should be avoided because rapid weight loss can cause ketosis, which competes with urate for renal excretion and may precipitate flares.

Low-Fat Dairy. The consumption of low-fat dairy products has been associated with a lower risk of gout in multiple prospective cohort studies. The proposed mechanism involves the uricosuric effect of milk proteins (casein and lactalbumin) and the anti-inflammatory properties of certain dairy-derived peptides. The ACR conditionally recommends incorporating low-fat or skim milk and yogurt into the diet.

Cherries. A small body of evidence suggests that cherry consumption reduces serum urate and may lower the risk of gout flares. Two servings of cherries per day (approximately 30–40 cherries) reduced the risk of acute flares by about 35% in one case-crossover study. The ACR made no formal recommendation for or against cherry intake, but given the low risk and potential benefit, many clinicians mention it as a reasonable adjunctive measure.

Hydration. Adequate fluid intake (at least 2–3 liters of water per day, adjusted for climate and activity) promotes urinary uric acid excretion and reduces the risk of uric acid nephrolithiasis. Patients should be encouraged to maintain good hydration, particularly during hot weather and when engaging in physical activity.

The DASH (Dietary Approaches to Stop Hypertension) and Mediterranean dietary patterns have been associated with lower serum urate levels and reduced gout incidence in observational studies. These diets emphasize fruits, vegetables, whole grains, low-fat dairy, lean protein, and healthy fats while limiting red meat, sugar, and saturated fat. The National Institute of Arthritis and Musculoskeletal and Skin Diseases provides patient-oriented resources at NIAMS Gout Diagnosis and Treatment.

Medication Table and Comparison

Medication	Class	Indication	Typical Dosing	Key Considerations
Naproxen	NSAID	Acute flare	500 mg twice daily x 5–7 days	GI protection needed; avoid in CKD, CHF, PUD
Indomethacin	NSAID	Acute flare	50 mg three times daily x 5–7 days	CNS side effects more common than other NSAIDs
Colchicine	Antimicrotubule	Acute flare & prophylaxis	1.2 mg then 0.6 mg 1 hr later; prophylaxis 0.6 mg/d	Diarrhea at higher doses; adjust in CKD; drug interactions
Prednisone	Corticosteroid	Acute flare	30–35 mg daily x 3–5 days then taper	Use when NSAIDs/colchicine contraindicated
Triamcinolone acetonide	Corticosteroid (IA)	Acute monoarticular flare	40–80 mg intra-articular	Exclude septic arthritis first
Allopurinol	Xanthine oxidase inhibitor	Chronic ULT	Start 100 mg/d; titrate to target urate <6 mg/dL	First-line ULT; HLA-B*58:01 screening in high-risk
Febuxostat	Xanthine oxidase inhibitor	Chronic ULT (second-line)	40–80 mg/d	Black-box CVD warning; allergic to allopurinol
Probenecid	Uricosuric	Chronic ULT (alternative)	250–1000 mg twice daily	Requires CrCl >50; avoid if kidney stone history
Pegloticase	Recombinant uricase (IV)	Refractory tophaceous gout	8 mg IV every 2 weeks	Infusion reactions; requires premedication

Comorbidities and Complications

Gout rarely exists in isolation. The majority of patients have one or more comorbid conditions that influence both gout management and overall cardiovascular and renal risk. Hypertension is present in up to 75% of gout patients, chronic kidney disease in 30–50%, type 2 diabetes in 20–30%, and hyperlipidemia in 40–60%. These associations are bidirectional: hyperuricemia may contribute to the development of hypertension and CKD through mechanisms including endothelial dysfunction, oxidative stress, and activation of the renin-angiotensin-aldosterone system, while diuretic therapy for hypertension exacerbates hyperuricemia.

The management of comorbidities in patients with gout requires careful medication selection. When possible, thiazide and loop diuretics should be avoided or replaced with alternative antihypertensives such as losartan (an angiotensin receptor blocker with uricosuric properties) or calcium channel blockers. Low-dose aspirin (81 mg daily) has a minimal but measurable effect on serum urate and is generally continued for cardiovascular protection when indicated; the ACR conditionally recommends against stopping low-dose aspirin for the purpose of gout management.

Fenofibrate, a fibric acid derivative used for hypertriglyceridemia, has mild uricosuric effects and may be preferred over statin monotherapy in patients with hypertriglyceridemia and gout, though the ACR conditionally recommends against adding or switching to fenofibrate specifically for urate lowering. SGLT2 inhibitors, increasingly prescribed for type 2 diabetes, heart failure, and CKD, also lower serum urate by approximately 0.5–1.0 mg/dL through increased urinary glucose and urate excretion, representing a potential therapeutic advantage for patients with gout and these comorbid conditions.

Untreated gout can lead to several complications. Chronic urate deposition can erode bone and cartilage, causing irreversible joint damage and deformity. Uric acid nephrolithiasis accounts for approximately 10–15% of all kidney stones, and the risk correlates with serum urate levels and urine acidity. Tophi can become inflamed, ulcerate, and discharge chalky material, increasing infection risk. Epidemiologic studies have also linked hyperuricemia and gout with an increased risk of cardiovascular events, though whether urate lowering independently reduces cardiovascular risk remains an area of active investigation. Data presented at EULAR 2026 confirmed that continued treat-to-target ULT is associated with modest kidney function benefits compared with ULT discontinuation, reinforcing the importance of lifelong therapy.

Long-Term Management and Emerging Therapies

Gout is a chronic disease that requires lifelong management for most patients. The ACR and EULAR both recommend continuing ULT indefinitely in a treat-to-target strategy, even during periods of remission. Data presented at EULAR 2026 from a randomized trial conducted across nine Dutch rheumatology clinics showed that 79.2% of patients who continued ULT with treat-to-target remained flare-free at 24 months compared with 62.9% of those who attempted ULT discontinuation. The cumulative flare incidence was 12.3% in the continuation group versus 31.8% in the discontinuation group, and patients who discontinued were significantly more likely to require anti-inflammatory rescue therapy. These findings support current guidelines recommending against ULT discontinuation in most patients.

Patient adherence to ULT is historically poor—fewer than 50% of patients are adherent at one year. Common reasons include the misconception that gout is an acute, self-limited condition rather than a chronic disease, frustration with the complexity of dose titration, and inadequate counseling about the rationale for prophylaxis during ULT initiation. Effective gout management requires clear communication from healthcare providers about the pathophysiology of gout, the distinction between acute and chronic treatment, the expected timeline of benefit (months to years for tophus resolution), and the importance of adherence even when symptoms are absent. Shared decision-making supported by the latest evidence from the American College of Rheumatology is available at ACR Gout Guideline.

Emerging therapies in gout management include IL-1 inhibitors (anakinra, canakinumab, rilonacept) for patients with frequent flares who cannot tolerate conventional anti-inflammatory options. A 2026 narrative review in the Journal of International Medical Research highlighted that biologic and gene-based treatments have demonstrated promising potential and may offer more personalized therapeutic solutions for patients with refractory gout. The role of SGLT2 inhibitors as adjunctive urate-lowering agents is an area of growing interest, with several observational studies suggesting clinically meaningful urate reduction. Finally, the 2026 ACR guideline update (anticipated later this year) may incorporate new evidence on ULT tapering strategies, the use of IL-1 blockade, and expanded indications for combination ULT in patients with severe tophaceous disease.

For patients and clinicians alike, the key message is clear: gout is a highly treatable condition when managed with a comprehensive, evidence-based approach that combines appropriate pharmacotherapy, dietary modification, weight management, and attention to comorbidities. With current treatment options, nearly all patients can achieve a serum urate target below 6 mg/dL, dissolve existing crystals, prevent future flares, and avoid the long-term complications of this ancient but eminently manageable disease.

For additional information, visit the CDC Gut Overview for public health information and basic gout education.

For additional information, visit Mayo Clinic Gout for comprehensive patient education on symptoms, causes, and treatment.

For additional information, visit Harvard Health Gout for expert-reviewed guidance on gout management and pain relief.

For additional information, visit the NIH / NIAMS Gout Information for research-backed resources and clinical trial information.

For additional information, visit American College of Rheumatology Gout Guideline for the full 2020 clinical practice guideline and updates.

This article is for informational purposes only and does not constitute professional medical advice. Always consult a qualified healthcare professional for specific guidance related to your health situation.